Profile
Kathleen Wilkinson is currently the Director at North Texas Commission and the Chief People Officer at Rapport Therapeutics, Inc. Formerly, Ms. Wilkinson was the Chief People Officer at 2seventy Bio, Inc. from 2022 to 2024, the Chief People Officer at bluebird bio, Inc. in 2021, and the Operations Director at Adnexus.
Ms. Wilkinson completed undergraduate studies at Harvard University.
Kathleen Wilkinson active positions
| Companies | Position | Start |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Human Resources Officer | 2024-01-31 |
North Texas Commission
North Texas Commission Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit membership-supported organization | Director/Board Member | - |
Former positions of Kathleen Wilkinson
| Companies | Position | End |
|---|---|---|
| 2SEVENTY BIO, INC. | Human Resources Officer | 2024-01-31 |
| GENETIX BIOTHERAPEUTICS, INC. | Human Resources Officer | 2021-11-30 |
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Develops medicines which includes protein antagonists | Chief Operating Officer | - |
Training of Kathleen Wilkinson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Adnexus
Adnexus Pharmaceuticals: MajorHealth Technology Develops medicines which includes protein antagonists | Health Technology |
North Texas Commission
North Texas Commission Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit membership-supported organization | Commercial Services |
2seventy Bio, Inc.
2seventy Bio, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for the treatment of cancer and genetic diseases | Health Technology |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder | Health Technology |
- Stock Market
- Insiders
- Kathleen Wilkinson
















